ELVN
NASDAQ
US
Enliven Therapeutics, Inc. - Common Stock
$38.83
▲ +$1.04
(+2.75%)
Vol 811K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$913.9M
ROE
-24.9%
D/E
0.00
Beta
0.27
52W
$13–$25
Wall Street Consensus
16 analysts · Apr 20265
Strong Buy
10
Buy
1
Hold
0
Sell
0
Strong Sell
93.8%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%
Next Report
May 12, 2026
EPS Estimate: $-0.47
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.47 | — | — |
| Dec 2025 | $-0.39 | $-0.48 | $-0.09 |
| Sep 2025 | $-0.44 | $-0.32 | +$0.12 |
| Jun 2025 | $-0.54 | $-0.49 | +$0.05 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$23.2M | -$28.5M | -$25.3M | -$20.1M | -$29.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -29.1% | -31.8% | -29.1% | -29.1% | -29.1% | -24.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 32.58 | 21.06 | 32.58 | 32.58 | 32.58 | 32.95 |
Key Ratios
ROA (TTM)
-24.0%
P/B
3.5
EPS (TTM)
$-1.85
CF/Share
$-0.72
52W High
$25.37
52W Low
$13.30
$13.30
52-Week Range
$25.37
Financial Health
Free Cash Flow
-$15.8M
Net Debt
-$98.5M
Cash
$98.9M
Total Debt
$399K
As of Dec 31, 2025
How does ELVN compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ELVN valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
3.6
▲
67%
above
peers
(2.1)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ELVN profitability vs Pharmaceuticals peers
ROE
-24.9%
▲
54%
above
peers
(-54.3%)
vs Peers
vs Industry
Below avg
Net margin
—
▼
0%
below
peers
(-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-24.0%
▲
36%
above
peers
(-37.4%)
vs Peers
vs Industry
Below avg
ELVN financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
33.0
▲
881%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.3
▼
71%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
ELVN fundamentals radar
ELVN
Peer median
Industry
ELVN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ELVN vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
COLLINS HELEN LOUISE
Officer · Mar 25
40000 shs
COLLINS HELEN LOUISE
Officer · Mar 25
40000 shs
COLLINS HELEN LOUISE
Officer · Mar 17
5000 shs
COLLINS HELEN LOUISE
Officer · Mar 17
5000 shs
COLLINS HELEN LOUISE
Officer · Mar 10
40000 shs
COLLINS HELEN LOUISE
Officer · Mar 10
40000 shs
HOHL BENJAMIN
Chief Financial Officer · Mar 06
10000 shs
COLLINS HELEN LOUISE
Officer · Feb 17
45000 shs
HEYMAN RICHARD A
Director · Feb 17
1230 shs
COLLINS HELEN LOUISE
Officer · Feb 17
45000 shs
Last 90 days
Top Holders
Top 5: 45.66%Orbimed Advisors LLC.
13.31%
$309.1M
FMR, LLC
11.89%
$276.0M
Commodore Capital Lp
7.85%
$182.2M
Vestal Point Capital, LP
6.40%
$148.7M
Fairmount Funds Management …
6.21%
$144.1M
As of Dec 31, 2025
Latest News
No related news yet